Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Larian Studios is apparently bullish on generative AI. Despite backlash against the technology from fans and even some of his own developers, studio head Swen Vincke says the Baldur’s Gate 3 maker has ...

According to DeepLearning.AI (@DeepLearningAI), leveraging ChatGPT to master Python serialization libraries like Pickle helps software developers efficiently serialize and deserialize complex objects ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Google today announced Gemini 3 with the goal of bringing “any idea to life.” The first model available in this family is Gemini 3 Pro with the rollout starting today for the Gemini app and AI Mode.

LinkedIn is launching its new AI-powered people search this week, after what seems like a very long wait for what should have been a natural offering for generative AI. It comes a full three years ...

Adobe Firefly feels like the best-kept secret in software right now. Adobe is aggressively talking up the app and its capabilities at events like Adobe MAX, but even with so much limelight, it doesn’t ...

Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Adobe assures its new AI model service is copyright-safe. Foundry models leverage Firefly and are trained on brands' IP. Tech companies are racing to deliver personalizable AI tools. In the age of ...